Spironolactone, eplerenone and the new aldosterone blockers in endocrine and primary hypertension

Spironolactone and risk of incident breast cancer in women older than 55 years: retrospective, matched cohort study

(2012) I. S. Mackenzie et al.   BMJ-British Medical Journal

Effects of a Novel Aldosterone Synthase Inhibitor for Treatment of Primary Hypertension

(2011) David A. Calhoun et al.   CIRCULATION

Addition of Spironolactone in Patients With Resistant Arterial Hypertension (ASPIRANT)

(2011) Jan Václavík et al.   HYPERTENSION

Results of the Randomized Aldosterone Antagonism in Heart Failure With Preserved Ejection Fraction Trial (RAAM-PEF)

(2011) Anita Deswal et al.   JOURNAL OF CARDIAC FAILURE

Aldosterone Blockers (Mineralocorticoid Receptor Antagonism) and Potassium-Sparing Diuretics

(2011) Murray Epstein et al.   Journal of Clinical Hypertension

A double-blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism

(2011) Hari K Parthasarathy et al.   JOURNAL OF HYPERTENSION

Molecular pharmacology of the mineralocorticoid receptor: Prospects for novel therapeutics

(2011) Peter Kolkhof et al.   MOLECULAR AND CELLULAR ENDOCRINOLOGY

A Randomized Study of the Beneficial Effects of Aldosterone Antagonism on LV Function, Structure, and Fibrosis Markers in Metabolic Syndrome

(2011) Wojciech Kosmala et al.   JACC-Cardiovascular Imaging

Cardiovascular and Renal Damage in Primary Aldosteronism: Outcomes After Treatment

(2010) L. A. Sechi et al.   AMERICAN JOURNAL OF HYPERTENSION

Spironolactone Management of Resistant Hypertension

(2010) Joel C Marrs   ANNALS OF PHARMACOTHERAPY

N-(Pyridin-3-yl)benzamides as selective inhibitors of human aldosterone synthase (CYP11B2)

(2010) Christina Zimmer et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

The L-, N-, and T-type triple calcium channel blocker benidipine acts as an antagonist of mineralocorticoid receptor, a member of nuclear receptor family

(2010) Hiromichi Kosaka et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Aldosterone Synthase Inhibition With LCI699

(2010) Laurence Amar et al.   HYPERTENSION

A New Mode of Mineralocorticoid Receptor Antagonism by a Potent and Selective Nonsteroidal Molecule

(2010) Jérôme Fagart et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

FAD286, an aldosterone synthase inhibitor, reduced atherosclerosis and inflammation in apolipoprotein E-deficient mice

(2010) Aviva Gamliel-Lazarovich et al.   JOURNAL OF HYPERTENSION

Stereochemical Requirements for the Mineralocorticoid Receptor Antagonist Activity of Dihydropyridines

(2010) Graciela B. Arhancet et al.   JOURNAL OF MEDICINAL CHEMISTRY

The effect of low-dose spironolactone on resistant hypertension

(2010) Mette Engbaek et al.   Journal of the American Society of Hypertension

Aldosterone: effects on the kidney and cardiovascular system

(2010) Marie Briet et al.   Nature Reviews Nephrology

Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms

(2010) Faiez Zannad et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy of Spironolactone Therapy in Patients With True Resistant Hypertension

(2009) Fabio de Souza et al.   HYPERTENSION

Cardiovascular and Cerebrovascular Comorbidities of Hypokalemic and Normokalemic Primary Aldosteronism: Results of the German Conn’s Registry

(2009) E. Born-Frontsberg et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Intrarenal Hemodynamics in Primary Aldosteronism before and after Treatment

(2009) Leonardo A. Sechi et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Spironolactone reduces severity of obstructive sleep apnoea in patients with resistant hypertension: a preliminary report

(2009) K Gaddam et al.   JOURNAL OF HUMAN HYPERTENSION

Aldosterone-receptor antagonism in hypertension

(2009) Pieter M Jansen et al.   JOURNAL OF HYPERTENSION

Aldosterone antagonism or synthase inhibition reduces end-organ damage induced by treatment with angiotensin and high salt

(2009) William B. Lea et al.   KIDNEY INTERNATIONAL

Triple Pharmacological Blockade of the Renin-Angiotensin-Aldosterone System in Nondiabetic CKD: An Open-Label Crossover Randomized Controlled Trial

(2008) Leszek Tylicki et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

Cardiovascular Outcomes in Patients With Primary Aldosteronism After Treatment

(2008) Cristiana Catena   ARCHIVES OF INTERNAL MEDICINE

Spironolactone use and the risk of upper gastrointestinal bleeding: a population-based case-control study

(2008) Sinem E. Gulmez et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Aldosterone synthase inhibition improves cardiovascular function and structure in rats with heart failure: a comparison with spironolactone

(2008) P. Mulder et al.   EUROPEAN HEART JOURNAL

Spironolactone versus eplerenone for the treatment of idiopathic hyperaldosteronism

(2008) Asterios Karagiannis et al.   EXPERT OPINION ON PHARMACOTHERAPY

Inappropriate Left Ventricular Mass in Patients With Primary Aldosteronism

(2008) Maria Lorenza Muiesan et al.   HYPERTENSION

A Number of Marketed Dihydropyridine Calcium Channel Blockers Have Mineralocorticoid Receptor Antagonist Activity

(2008) Jessica D. Dietz et al.   HYPERTENSION

Resistant Hypertension: Diagnosis, Evaluation, and Treatment

(2008) David A. Calhoun et al.   HYPERTENSION

Effect of Renin-Angiotensin-Aldosterone System Triple Blockade on Non-Diabetic Renal Disease: Addition of an Aldosterone Blocker, Spironolactone, to Combination Treatment with an Angiotensin-Converting Enzyme Inhibitor and Angiotensin II Receptor Blocker

(2008) Yoshiyuki FURUMATSU et al.   HYPERTENSION RESEARCH

Case Detection, Diagnosis, and Treatment of Patients with Primary Aldosteronism: An Endocrine Society Clinical Practice Guideline

(2008) John W. Funder et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Risk Factors Associated with a Low Glomerular Filtration Rate in Primary Aldosteronism

(2008) Martin Reincke et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Spironolactone and gastrointestinal bleeding: a population based study

(2008) Antonio Russo et al.   PHARMACOEPIDEMIOLOGY AND DRUG SAFETY

Primary aldosteronism: cardiovascular, renal and metabolic implications

(2008) Gian-Paolo Rossi et al.   TRENDS IN ENDOCRINOLOGY AND METABOLISM